BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19619445)

  • 1. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
    Wang B; Fu JF; Hong ZW
    Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
    Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].
    Taguchi T; Masuda N; Nakayama T; Motomura K; Tsukamoto F; Shimazu K; Nomura T; Morimoto T; Yamamoto H; Wakita K; Nakano Y; Yoneda K; Inaji H; Takatsuka Y; Noguchi S;
    Oncology; 2010; 78(5-6):302-8. PubMed ID: 20606491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
    Hui R; Zhang M; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?
    Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1452-9. PubMed ID: 20605368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
    Darut-Jouve A; Coudert B; Jolimoy G; Belichard C; Arnoud L; Guerrin J
    Bull Cancer; 1999 Feb; 86(2):189-94. PubMed ID: 10066950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
    Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
    Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
    Sinn HP; Schmid H; Junkermann H; Huober J; Leppien G; Kaufmann M; Bastert G; Otto HF
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):552-8. PubMed ID: 8001751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
    Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.